Citations

Showing 10 of 108094 citations.

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
Riviere-Cazaux, Cécile , Neth, Bryan J. , Rahman, Masum , Kizilbash, Sani H. , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i9-i9

10.1093/noajnl/vdac078.034 Get It

Abstract Gliomas may leverage alternate metabolic pathways in response to metabolism-targeted therapeutic intervention, all of which remain unexplored in the live human glioma, in situ. Defining emergent mechanisms of metabolic resistance in response to therapeutic challenge can help guide rational combinatorial therapies. To date, the metabolic response of gliomas in response to therapeutic intervention has remained poorly understood due to the relative inaccessibility of the live human tumor, in situ. Microdialysis is an underutilized tool that could be leveraged to overcome this longstanding challenge. Data from our ongoing intraoperative microdialysis trial have revealed an upregulation of polyamine metabolism and a novel glioma-associated metabolite, guanidinoacetate (GAA) -- a metabolite co-produced with ornithine, which is required for polyamine synthesis. In a Phase 0 trial, we will evaluate in situ glioma responses to polyamine depletion (difluoromethylornithine, DFMO) with or without blockade of polyamine uptake (AMXT 1501) to identify candidate extracellular biomarkers of target engagement and cytotoxicity in fifteen post-operative patients who have undergone a standard-of-care planned subtotal resection for high-grade glioma. Intraoperatively, high-molecular-weight catheters will be implanted into the residual tumor and brain adjacent to the resection cavity for post-operative longitudinal monitoring of extracellular metabolites via microdialysis. Polyamines and guanidinoacetate, a candidate biomarker of glioma-upregulated polyamine synthesis, will be monitored throughout therapeutic intervention from post-operative day (POD) 1 to POD5 via longitudinal microdialysis to determine live in situ glioma pharmacodynamic responses to polyamine depletion. Catheters will be removed on post-operative day five prior to discharge. We hypothesize that GAA will reflect local tumor production of polyamine metabolism. Additionally, in situ microdialysis in Phase 0 trials will allow for pharmacodynamic and pharmacokinetic, in addition to metabolic, monitoring, an opportunity which is rarely afforded in most clinical trials due to lack of access to the CNS.
CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
Brown, Paul D. , Gondi, Vinai , Ahluwalia, Manmeet S. , Ahluwalia, Manmeet S , Mehta, Minesh P.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i8-i8

10.1093/noajnl/vdac078.030 Get It

Abstract BACKGROUND Tumor Treating Fields (TTFields) are electric fields that disrupt cancer cell division. TTFields treatment showed efficacy in preclinical non-small cell lung cancer (NSCLC) models. Furthermore, TTFields therapy improved survival with a tolerable safety profile in patients with glioblastoma. The objective of the pivotal METIS trial [NCT02831959] is to evaluate the efficacy and safety of TTFields therapy in NSCLC patients with brain metastases. METHODS NSCLC patients (N=270) with 1–10 brain metastases will be randomized 1:1 to stereotactic radiosurgery (SRS) followed by continuous TTFields therapy using NovoTTF-200M (150 kHz, recommended >18 h/day) with best standard of care (BSC) or SRS followed by BSC alone. Follow-ups will be conducted every 2 months until second intracranial progression. Key inclusion criteria are: Karnofsky Performance Status ≥70, new diagnosis of 1 inoperable or 2–10 supra- and/or infratentorial brain metastases from NSCLC amenable to SRS, and optimal therapy for extracranial disease. Key exclusion criteria are: prior whole brain radiotherapy, single operable, or recurrent brain metastases. Primary endpoint is time to first intracranial progression. Secondary endpoints include time to neurocognitive failure, overall survival, radiological response rate (RANO-BM and RECIST V1.1), quality of life, adverse events, time to first/second intracranial progression for patients with 1–4 and 5–10 brain metastases, bi-monthly intracranial progression rate from 2–12 months, and time to second intracranial and distant progression. The study is powered at 80% (2-sided alpha of 0.05) to detect a hazard ratio of 0.57. In July 2021, an independent Data Monitoring Committee (DMC) reviewed the study data and recommended continuation as planned. The trial is currently recruiting at 92 sites in North America, Europe, Israel, mainland China and Hong Kong.
BSCI-10 TAPPING INTO GLIOMAS’ SECRETS: CSF PROTEOMICS FOR BIOMARKER DISCOVERY, GLIOMA MONITORING, AND THERAPEUTIC RESPONSE ASSESSMENT
Riviere-Cazaux, Cécile , Ikram, Samar, Chantigian, Siobhan, Warrington, Arthur E. , Rahman, Masum , Burns, Terry C.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i3-i3

10.1093/noajnl/vdac078.009 Get It

Abstract INTRODUCTION Rapid, detailed feedback is needed to understand the individualized biological impacts of novel glioma therapies. We are performing glioma biomarker discovery by serial cerebrospinal fluid (CSF) sampling from Ommaya reservoirs to determine how the CSF proteome can reveal early longitudinal intelligence regarding glioma status, biology, and therapeutic response. METHODS Global proteomic analysis of CSF was performed on the Somalogic platform − an aptamer-based technology for highly sensitive and specific analysis of over 7,000 proteins. Discovery analysis comprised of the top-500 ranked proteins in CSF from seven patients with high-grade gliomas (HGG) versus non-glioma controls. The top-500 HGG proteins were then preliminarily filtered to include only proteins that met two additional criteria of decrease with resection and increase with recurrence in individual paired patient samples. RESULTS Proteomic enrichment analysis revealed a conserved HGG CSF proteomic signature defined by 79 proteins, including ones known to be over-expressed in solid tumor malignancies, such as retinoblastoma binding protein 4, heat shock protein 90, and sorcin. The HGG proteomic signature was consistently enriched in an independent validation cohort consisting of 13 gliomas diverse in primary versus recurrent status, subtype, and grade, when compared to control CSF samples. Encouragingly, proteins in the HGG signature decreased in the two patients for whom CSF was collected prior to and after resection (both at POD16 and POD18) with decreased tumor burden. CONCLUSION Our preliminary data demonstrate the ability to gain detailed, individualized insights regarding glioma biology, tumor burden, and evolution through global CSF proteomics acquired from longitudinal neurosurgical access to unique gliomas.
Meniscal Extrusion
Kaiser, Joshua T. , Damodar, Dhanur , Udine, Matthew , Meeker, Zachary D. , McCormick, Johnathon R. , Wagner, Kyle R. , Krych, Aaron J. , Chahla, Jorge , Cole, Brian J. , Udine, Matthew J , Chahla, Jorge A , Krych, Aaron J

Mayo Clinic

JBJS Reviews | August 5, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.2106/jbjs.rvw.22.00019 | PMID 35922395 Get It

➢ Pathologic meniscal extrusion can compromise meniscal function, leading to increased contact forces in the tibiofemoral compartment and the acceleration of osteoarthritic changes. ➢ Extrusion is typically defined as radial displacement of ≥3 mm outside the tibial border and is best diagnosed via magnetic resonance imaging, although ultrasonography has also demonstrated encouraging diagnostic utility. ➢ Surgical management of meniscal extrusion is based on the underlying etiology, the patient’s symptom profile, the preexisting health of the articular surface, and the risk of future chondral injury and osteoarthritis.
The Trillat Procedure for Anterior Glenohumeral Instability
Garcia, Ausberto Velasquez , Chaney, Grace K. , Martini, Liborio Ingala , Valenti, Philippe , Velasquez Garcia, Ausberto , Ingala Martini, Liborio

Mayo Clinic

JBJS Reviews | August 5, 2022 | Volume: 10 | Issue: 8 | Pages: No page available

10.2106/jbjs.rvw.22.00049 | PMID 35922397 Get It

» Anterior glenohumeral instability (AGI) is a challenging condition that requires close attention to osseous and soft-tissue abnormalities. The morphometric variance of the periarticular scapular anatomy may be involved in the pathogenesis of recurrent traumatic anterior instability. » The Trillat procedure repositions the coracoid medially and downward by a partial wedge osteotomy, mimicking the sling effect of the Latarjet procedure by moving the conjoint tendon closer to the joint line in throwing position. The Trillat procedure decreases the coracohumeral distance without affecting the integrity of the subscapularis muscle and tendon. » Joint preservation methods, such as the Trillat procedure, may be explored in older patients to treat AGI with simultaneous irreparable rotator cuff tears (RCTs) with a static centered head and a functional subscapularis. » Shoulder hyperlaxity and instability can be challenging to treat with isolated soft-tissue procedures. In cases without glenoid bone loss, free bone block techniques are ineffective because of the subsequent potential graft resorption, apprehension, or recurrence. The Trillat surgery, in conjunction with an anteroinferior capsuloplasty, seems to be helpful in preventing recurrent instability and in reducing shoulder apprehension. » Recently, several variations of the original technique have been described. In the future, anatomical, biomechanical, and clinical studies need to be conducted to further evaluate the morphometric characterization of the procedure, enhance the technical features, improve indications, and avoid coracoid impingement and other potential complications with the Trillat procedure.
SYST-13 PHASE II STUDY OF THE COMBINATION OF LIPOSOMAL IRINOTECAN AND PEMBROLIZUMAB FOR TRIPLE-NEGATIVE BREAST CANCER (TNBC) WITH BRAIN METASTASES (BM)
Xi, Jing , Luo, Jingqing, O’Sullivan, Ciara C. , Chen, Nan , Stringer-Reasor, Erica , Cynthia, X. , Campian, Jian

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i24-i24

10.1093/noajnl/vdac078.092 Get It

Abstract BACKGROUND Breast cancer is one of the most common cancers associated with brain metastases (BM). Up to 50% of patients with metastatic triple-negative breast cancer (TNBC) develop BM which portends a poor prognosis, with a median survival of 4.4-7.3 months. There is a lack of effective systemic therapy. Irinotecan is a topoisomerase-1 inhibitor with a response rate of 5-23% in advanced breast cancer. Nal-IRI is an intravenous liposomal formulation of irinotecan, with greater efficacy in tumor growth inhibition and the ability to cross the blood brain barrier (BBB) than irinotecan, resulting in a prolonged survival in preclinical TNBC BM models. Additionally, Nal-IRI has demonstrated promising anti-tumor activity in patients with TNBC- BM in a phase-I trial (NCT01770353). Pembrolizumab is a humanized anti-PD-1 monoclonal antibody which has shown efficacy in TNBC. The purpose of this study is to evaluate whether the combination of Nal-IRI and pembrolizumab can provide a synergic effect to control the CNS disease and prolong survival in TNBC with progressive BM. METHODS This is a phase II, single arm trial with a safety lead-in to evaluate the efficacy of nal-IRI (50-70mg/m2 IV Q2W) in combination with pembrolizumab (400mg IV Q6W). Simon’s 2-stage design is used, with 18 patients in the 1st stage and additional 24 at 2nd stage for a total of 42. The first 6 patients will serve as a safety lead-in. Key eligibilities include: histologically/cytologically confirmed TNBC with new or progressive BM; prior immunotherapy is allowed but not prior nal-IRI/irinotecan; prior sacituzumab-govitecan is permitted if disease stable for ≥16-week while on therapy and ≥24-week washout prior to starting trial; measurable disease; and ≤4 prior lines of therapy in the metastatic setting. The primary endpoint is CNS disease control rate (DCR) at 6 months using RANO-BM criteria. Secondary endpoints include CNS and non-CNS ORR, PFS and OS. (ClinicalTrials.gov: NCT05255666)
LOCL-03 INTRATUMORAL DELIVERY OF CONDITIONALLY REPLICATIVE HUMAN ADENOVIRUS 657 EXPRESSING THE IMMUNE CO-STIMULATOR CD40L (CRAD657-CD40L) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA
Khatua, Soumen , Thompson, Jill , Yerovi, Maria Chiriboga , Schartz, Jonathan, Wongthida, Phonphimon , Hopps, Sidney, Barry, Mary, Vile, Richard G. , Díaz, Rosa María, Webb, Mason , Daniels, David J. , Barry, Michael A.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i12-i12

10.1093/noajnl/vdac078.045 Get It

Abstract INTRODUCTION Malignancies of the central nervous system (CNS) have had largely unchanged survival outcomes despite decades of research. Recently, viral-based therapeutics have shown some benefit for patients with CNS malignancies in early clinical trials. Adenovirus has been demonstrated as safe and is currently being examined in several phase I and II clinical trials. We recently demonstrated that adenovirus expressing CD40L is effective in enhancing survival in murine models of diffuse midline glioma. Therefore, to enhance the tumor specificity of this virotherapy, we hypothesized that by using a novel conditionally replicative adenovirus expressing CD40L, CRAd657-CD40L, we would maintain this survival benefit in multiple murine models for high grade glioma while decreasing off-target toxicity. METHODS We examined the utility of conditionally replicative adenovirus expressing CD40L in both in vitro and in vivo studies. Human cell lines from diffuse intrinsic pontine glioma (DIPG) and glioblastoma were used to confirm infectivity and CD40L expression, and syngeneic murine models of glioma were evaluated for toxicity and survival following intratumoral injection of a conditionally replicative adenoviral vector. RESULTS CRAd657-CD40L generated strong expression of CD40L in human in vitro DIPG XIII and U251 cell lines and induced MHCII expression on CD11c+ DC’s in U251/DC co-culture. Further, in syngeneic murine models of glioma, conditionally replicative adenoviral treatment significantly reduced toxicity while retaining survival efficacy. CONCLUSIONS Given these promising results as well as the critical need for novel therapeutics in CNS malignancies, we are now progressing to human trials targeting pediatric HGG, an unmet need in pediatric neuro-oncology. This would be the first-in-human study using CRAd-657-CD40L in pediatric HGG. In this Phase 1 clinical trial, we hypothesize that intratumoral injection of CRAd657-CD40L will cause selective expression of CD40L, increased infiltration of immune cells into the tumor, and safely enhance tumor clearance.
NEIM-02 DEVELOPMENT OF A DEEP LEARNING MODEL FOR DISCRIMINATING TRUE PROGRESSION FROM PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS
Moassefi, Mana, Faghani, Shahriar , Erickson, BradleyJ, Faghani, Shahriar , Moassefi, Mana , Conte, Gian Marco , Rouzrokh, Pouria , Kowalchuk, Roman O. , Trifiletti, Daniel M. , Erickson, Bradley J.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i17-i18

10.1093/noajnl/vdac078.069 Get It

Abstract INTRODUCTION Glioblastomas (GBMs) are highly aggressive tumors. Despite multimodal treatment, its median overall survival ranges between 16 and 20 months. The standard treatment regimen consists of surgical resection followed by concurrent chemoradiotherapy and adjuvant temozolomide. Despite temozolomide’s effectiveness, it may cause the clinical challenge of treatment-related progression also known as pseudoprogression(PsP). Usually, PSP resolves or stabilizes without further treatment, whereas a true progression (TP) requires more aggressive management. Identifying PSP from TP will affect the patient’s treatment plan. Conventional magnetic resonance imaging (MRI) reading techniques cannot distinguish these entities. This study investigated the feasibility of using deep learning to distinguish PsP from TP. METHOD We included GBM patients who met our inclusion criteria. We evaluated all cases to see if they had a new enhancing lesion within the original radiation field or an increase in the size of an existing lesion. The challenging MRIs were collected. Clinical notes regarding tumor and recurrence location, clinical history, and medication were collected. We labeled the ones who stayed stable or improved in the imaging and clinical situation as PSP and those with further imaging and clinical deterioration as TP. We coregistered Contrast-enhanced-T1 MRIs with T2-weighted images for each patient. We performed five-fold cross-validation to generalize the performance. We trained A 3-D Densenet121 model to establish the prediction. We selected the best models with the highest accuracy. RESULT After reviewing 1000 patients, we included 124 patients whose imaging showed suspicious progression and their medicational histories were completely retrievable; 63 PsP, and 61 TP. We developed a deep learning model based on the whole dataset. The 5-fold cross-validation revealed that the mean area under the curve (AUC) was 0.81. CONCLUSION We report the development of a deep learning model that diagnoses PsP from TP in patients who received temozolomide. Further refinement and external validation are required prior to widespread adoption in clinical practice.
LOCL-07 LOCO-REGIONAL INFUSION OF GB-13 (IL13.E13K-PE4E) AS A POTENTIALLY PROMISING TREATMENT FOR RECURRENT HIGH-GRADE GLIOMA
Khatua, Soumen , Campian, Jian , Schwartz, Jonathan , Schrecengost, Randy S., Rechberger, Julian S. , Sarkaria, Jann N. , Daniels, David J.

Mayo Clinic

Neuro-Oncology Advances | August 5, 2022 | Volume: 4 | Issue: Supplement_1 | Pages: i13-i13

10.1093/noajnl/vdac078.049 Get It

Abstract INTRODUCTION High grade gliomas (HGG) are devastating diseases with largely unchanged survival outcomes despite decades of research. Recent studies suggest the interleukin 13 receptor subunit alpha 2 (IL-13Rα2) is selectively upregulated in up to 80% of HGG, including glioblastoma (GBM) and diffuse midline gliomas (DMG) harboring H3K27 alterations. Immunotoxins targeting IL-13Rα2 have been demonstrated as safe and have shown some benefit for patients with HGG in previous phase I/II and III clinical trials. We hypothesized that by using GB-13 (IL13.E13K-PE4E), a novel peptide-toxin that binds IL-13Rα2 with high specificity and possesses a Pseudomonas exotoxin moiety, we would enhance the anti-tumor effects of this immunotherapy for HGG in vitro and in vivo while decreasing off-target toxicity. METHODS We examined the pharmacological effects of GB-13 in multiple patient-derived cell lines and rodent models of HGG. GBM and DMG lines were used to confirm IL-13Rα2 expression and sensitivity towards GB-13. Tumor naïve rats were evaluated for toxicity, and orthotopic PDX mice were used to monitor tumor size and survival following loco-regional infusion of GB-13. RESULTS GB-13 induced a potent cytotoxic response strongly predicated on IL-13Rα2 expression in vitro. No treatment-related adverse effects were noted after 7-day continuous intracranial infusion of GB-13 in tumor naïve rats. Further, in IL-13Rα2-upregulated orthotopic PDX mice, direct intratumoral administration of GB-13 via convection-enhanced delivery abrogated tumor growth and prolonged survival. CONCLUSIONS Given these promising results as well as the critical need for novel therapies in CNS malignancies, we are progressing to human trials using GB-13 targeting recurrent HGG. Ongoing safety studies in tumor-bearing animals will be able to define dose levels for the initial adult study-arm and the following pediatric study-arm. In this Phase 1 clinical trial, we hypothesize that loco-regional infusion of GB-13 will safely enhance tumor clearance by causing selective killing of IL-13Rα2-upregulated HGG cells.
The Impact of COVID-19 on Physician–Scientist Trainees and Faculty in the United States: A National Survey
Kwan, Jennifer M. , Noch, Evan , Qiu, Yuqing , Toubat, Omar , Christophers, Briana , Azzopardi, Stephanie A. , Gilmer, Gabrielle , Wiedmeier, Julia E. , Daye, Dania , Wiedmeier, Julia Erin, Wiedmeier-Nutor, Julia E

Mayo Clinic

Academic Medicine | August 5, 2022 | Volume: 97 | Issue: 10 | Pages: 1536-1545

10.1097/acm.0000000000004802 | PMID 35921163 Get It

Abstract Purpose Physician–scientists have long been considered an endangered species, and their extended training pathway is vulnerable to disruptions. This study investigated the effects of COVID-19-related challenges on the personal lives, career activities, stress levels, and research productivity of physician–scientist trainees and faculty. Method The authors surveyed medical students (MS), graduate students (GS), residents/fellows (R/F), and faculty (F) using a tool distributed to 120 U.S. institutions with MD–PhD programs in April–June 2020. Chi-square and Fisher’s exact tests were used to compare differences between groups. Machine learning was employed to select variables for multivariate logistic regression analyses aimed at identifying factors associated with stress and impaired productivity. Results The analyses included 1,929 respondents (MS: n = 679, 35%; GS: n = 676, 35%; R/F: n = 274, 14%; F: n = 300, 16%). All cohorts reported high levels of social isolation, stress from effects of the pandemic, and negative impacts on productivity. R/F and F respondents were more likely than MS and GS respondents to report financial difficulties due to COVID-19. R/F and F respondents with a dual degree expressed more impaired productivity compared with those without a dual degree. Multivariate regression analyses identified impacted research/scholarly activities, financial difficulties, and social isolation as predictors of stress and impaired productivity for both MS and GS cohorts. For both R/F and F cohorts, impacted personal life and research productivity were associated with stress, while dual-degree status, impacted research/scholarly activities, and impacted personal life were predictors of impaired productivity. More female than male respondents reported increased demands at home. Conclusions This national survey of physician–scientist trainees and faculty found a high incidence of stress and impaired productivity related to the COVID-19 pandemic. Understanding the challenges faced and their consequences may improve efforts to support the physician–scientist workforce in the postpandemic period.